Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction

Abstract

The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.

1 . A method for improving glycemic control in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient, wherein the patient is a male patient diagnosed with erectile dysfunction. 
     
     
         2 . A method for treating erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient. 
     
     
         3 . The method according to  claim 1 , wherein the patient is a poor-responder or a non-responder to a treatment with a PDE5 inhibitor. 
     
     
         4 . The method according to  claim 1 , wherein the patient is over the age of 60 years. 
     
     
         5 . The method according to  claim 1 , wherein the patient has insufficient glycemic control despite antidiabetic treatment with one or more medicaments not including SGLT2 inhibitors. 
     
     
         6 . The method according to  claim 1 , wherein in addition to the administration of a SGLT2 inhibitor one or more antidiabetic medicaments not belonging to the class of SGLT2 inhibitors are administered to the patient. 
     
     
         7 . The method according to  claim 1 , wherein the SGLT2 inhibitor is empagliflozin. 
     
     
         8 . The method according to  claim 7 , wherein empagliflozin is administered in an amount of 2.5 to 25 mg. 
     
     
         9 . A method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient in addition to the treatment of erectile dysfunction. 
     
     
         10 . The method according to  claim 9 , wherein the treatment of erectile dysfunction comprises the administration of one or more medicaments selected from the group consisting of PDE5 inhibitors or alprostadil. 
     
     
         11 . The method according to  claim 9 , wherein the SGLT2 inhibitor is empagliflozin. 
     
     
         12 . The method according to  claim 11 , wherein empagliflozin is administered in an amount of 2.5 to 25 mg. 
     
     
         13 . A pharmaceutical composition comprising a SGLT2 inhibitor and one or more compounds selected from the group consisting of PDE5 inhibitors, apomorphin or alprostadil. 
     
     
         14 . The pharmaceutical composition according to  claim 13 , wherein the SGLT2 inhibitor is empagliflozin. 
     
     
         15 . The pharmaceutical composition according to  claim 13 , wherein the amount of empagliflozin is from 2.5 to 25 mg.